Epigenetic inactivation of the RUNX3 gene in lung cancer
- PMID: 16328045
Epigenetic inactivation of the RUNX3 gene in lung cancer
Abstract
The silencing of tumor suppressor genes (TSGs) by aberrant hypermethylation occurs frequently in human cancer. Recently the RUNX3 gene was identified as a TSG inactivated by hypermethylation. We examined RUNX3 expression by reverse transcription-PCR and the methylation status of this gene by methylation specific-PCR in 43 lung cancer cell lines and 120 primary non-small cell lung cancer (NSCLC) tumor samples. RUNX3 expression was absent in 10 (50%) of 20 small cell lung cancer (SCLC) cell lines, 8 (50%) of 16 adenocarcinoma (AdC) cell lines, and 1 (33.3%) of 3 squamous cell carcinoma (SqC) cell lines. The frequency of RUNX3 methylation was significantly higher in AdC (7/16, 43.8%) than SCLC cell lines (1/20, 5%; p=0.032). RUNX3 expression was restored by treatment with 5-aza-2'-deoxycytidine and/or trichostatin-A in AdC cell lines. These results indicated that RUNX3 expression was regulated by aberrant hypermethylation in AdC cell lines. RUNX3 methylation was detected in 30 (25%) of 120 primary NSCLC tumors. RUNX3 methylation was significantly more frequent in non-smokers (16/43, 37.2%) than smokers (12/71, 16.9%; p=0.014), and in patients with AdC (26/72, 36.1%) than in patients with SqC (3/45, 6.7%; p<0.001). These results indicated that silencing of the RUNX3 gene plays an important role in the pathogenesis of lung cancer, and aberrant methylation is an important mechanism of inactivation of the RUNX3 gene in lung AdC.
Similar articles
-
Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.Lung Cancer. 2007 Oct;58(1):131-8. doi: 10.1016/j.lungcan.2007.05.011. Epub 2007 Jul 2. Lung Cancer. 2007. PMID: 17606310
-
Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.Pathobiology. 2008;75(4):244-51. doi: 10.1159/000132385. Epub 2008 Jun 26. Pathobiology. 2008. PMID: 18580070
-
Frequent hemizygous deletion at 1p36 and hypermethylation downregulate RUNX3 expression in human lung cancer cell lines.Oncol Rep. 2005 Oct;14(4):817-22. Oncol Rep. 2005. PMID: 16142337
-
Molecular genetics of small cell lung carcinoma.Semin Oncol. 2001 Apr;28(2 Suppl 4):3-13. Semin Oncol. 2001. PMID: 11479891 Review.
-
RUNX3 is multifunctional in carcinogenesis of multiple solid tumors.Oncogene. 2010 May 6;29(18):2605-15. doi: 10.1038/onc.2010.88. Epub 2010 Mar 29. Oncogene. 2010. PMID: 20348954 Review.
Cited by
-
Advances in cancer DNA methylation analysis with methPLIER: use of non-negative matrix factorization and knowledge-based constraints to enhance biological interpretability.Exp Mol Med. 2024 Mar;56(3):646-655. doi: 10.1038/s12276-024-01173-7. Epub 2024 Mar 4. Exp Mol Med. 2024. PMID: 38433247 Free PMC article.
-
Epigenetics of lung cancer.Transl Res. 2015 Jan;165(1):74-90. doi: 10.1016/j.trsl.2014.03.001. Epub 2014 Mar 12. Transl Res. 2015. PMID: 24686037 Free PMC article. Review.
-
Epigenetic alteration of Wnt pathway antagonists in progressive glandular neoplasia of the lung.Carcinogenesis. 2008 May;29(5):895-904. doi: 10.1093/carcin/bgn017. Epub 2008 Feb 28. Carcinogenesis. 2008. PMID: 18308762 Free PMC article.
-
Clinicopathological significance and potential drug target of RUNX3 in non-small cell lung cancer: a meta-analysis.Drug Des Devel Ther. 2015 Jun 3;9:2855-65. doi: 10.2147/DDDT.S76358. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26082616 Free PMC article.
-
Epigenetic regulation in lung cancer.MedComm (2020). 2023 Oct 26;4(6):e401. doi: 10.1002/mco2.401. eCollection 2023 Dec. MedComm (2020). 2023. PMID: 37901797 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous